Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

834
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
834
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

783
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
783
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

748
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
748
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

852
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
852
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

670
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
670
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

432
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
432

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigating Physical Exercise and Cognitive Training Effects on Cognition and Brain Health in Men and Women with Heart Failure: The ReCARDIO Trial.

CJC open·2026
Same author

A multicenter randomized single-blinded clinical trial to investigate the effects of an individualized home-based cognitive training program in patients with chronic heart failure: the SYNAPSE protocol.

Trials·2025
Same author

CAEP Acute Heart Failure Best Practices Checklist.

CJEM·2025
Same author

Vaccination in patients with heart failure in practice.

European journal of preventive cardiology·2025
Same author

Aortic Valve Calcification Is Induced by the Loss of ALDH1A1 and Can Be Prevented by Agonists of Retinoic Acid Receptor Alpha: Preclinical Evidence for Drug Repositioning.

Circulation·2025
Same author

Multimodality Imaging Findings in Cardiac Plasmacytoma.

JACC. Case reports·2025

Related Experiment Video

Updated: Apr 7, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K

[Peripartum cardiomyopathy].

Frédéric Mouquet1, Nadia Bouabdallaoui2

  • 1Polyclinique du Bois, soins intensifs et cardiologie, 59000 Lille, France; Institut pasteur de Lille, Inserm UMR 1011, 59000 Lille, France.

Presse Medicale (Paris, France : 1983)
|July 11, 2015
PubMed
Summary

Peripartum cardiomyopathy is a rare heart condition affecting pregnant women, diagnosed by heart failure symptoms and reduced systolic function. While treatable, subsequent pregnancies are discouraged if heart function doesn't fully recover.

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.5K

Related Experiment Videos

Last Updated: Apr 7, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.5K

Area of Science:

  • Cardiology
  • Obstetrics
  • Maternal-Fetal Medicine

Context:

  • Peripartum cardiomyopathy (PPCM) is a rare form of heart failure.
  • It develops in the final month of pregnancy or within five months postpartum.
  • PPCM is linked to changes in blood vessel formation (angiogenesis) during late pregnancy.

Purpose:

  • To define peripartum cardiomyopathy.
  • To outline diagnostic criteria and differential diagnoses.
  • To identify risk factors and management strategies.
  • To discuss prognosis and implications for future pregnancies.

Summary:

  • Diagnosis involves clinical heart failure signs and impaired systolic function (echocardiography/cardiac MRI), excluding other cardiac conditions.
  • Key risk factors include advanced maternal age, multiple births, twin pregnancy, African ancestry, obesity, preeclampsia, gestational hypertension, and prolonged tocolytic use.
  • Acute treatment mirrors standard systolic heart failure management. Vitamin K antagonists (VKAs) are considered for severe systolic dysfunction (<25%) due to thrombus risk. Bromocriptine may be used selectively.
  • Approximately 50% of patients experience complete systolic function recovery. Mortality risk is low, but future pregnancies are generally discouraged, particularly if cardiac function remains impaired.

Impact:

  • Improves understanding of PPCM diagnosis and risk stratification.
  • Provides guidance on acute and long-term management strategies.
  • Highlights the importance of considering cardiac function in postpartum care and family planning.